Cholangiocarcinoma

The FIDES-01 clinical trial showed encouraging preliminary results for derazantinib as a second-line treatment in patients with intrahepatic cholangiocarcinoma harboring FGFR2 alterations.

Despite differences in baseline prognostic characteristics identified by the regional analysis of the TOPAZ-1 study, outcomes between the regions were generally similar.

Assessment of patient-reported outcomes revealed no clinically meaningful detriment occurred with the addition of durvalumab to gemcitabine/cisplatin in advanced biliary tract cancers.

Derazantinib was found to provide clinical benefit in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 mutations or amplifications.

Analysis of the phase 3 ABC-06 trial revealed limited prognostic utility of the tumor marker CA19.9 after initiation of FOLFOX.

A comparison of clinical trials found progression-free survival with futibatinib to be significantly greater compared with chemotherapy and that trials favor futibatinib over pemigatinib for all efficacy parameters.

Immune-related adverse events in the TOPAZ-1 trial were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival.

A systematic review of phase 2 and 3 clinical trials for biliary tract cancers revealed quality-of-life assessments were not routinely included as trial outcomes.

The phase 2 STAMP study revealed negligible differences in disease-free survival and overall survival between adjuvant gemcitabine/cisplatin versus capecitabine in lymph node–positive extrahepatic cholangiocarcinoma but found increased grade 3/4 adverse events with gemcitabine/cisplatin.

Investigators found the addition of toripalimab to a gemcitabine-based chemotherapy regimen as first-line treatment of advanced biliary tract cancers demonstrated encouraging efficacy.